Список проголосовавших за комментарий " On The Wires<ul><li>AbbVie (<strong>ABBV</strong>) announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer's disease and progressive supranuclear palsy (PSP). In recognition of the lack of treatment options available to patients with PSP, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to ABBV-8E12. The FDA and European Medicines Agency (EMA) also granted Orphan Drug Designations to ABBV-8E12 for PSP.1,2</li><li>Daktari Diagnostics announced that it has reached a milestone in its global collaboration with Merck (<strong>MRK</strong>), known as MSD outside the United States and Canada, for the development of Daktari's rapid point-of-care hepatitis C virus core antigen confirmatory test system. Daktari has successfully completed the design of the cartridge prototype suitable for commercial production, triggering a milestone payment of an undisclosed sum from Merck.</li><li>Esperion Therapeutics (<strong>ESPR</strong>) announced completion of patient enrollment in the global pivotal Phase 3 long-term safety and tolerability study of bempedoic acid. Enrollment of this study was completed ahead of schedule in approximately 2,000 patients treated with bempedoic acid or placebo at high cardiovascular disease risk with hypercholesterolemia whose LDL-C is not adequately controlled with current lipid-modifying therapies. Top-line results from this study are expected by Q2 2018.</li><li>NTL FCStone (<strong>INTL</strong>) announced it was responsible for OTC trades totaling approximately $26.6 billion in 2016, +27% over 2015. </li><li>Williams Partners L.P. (<strong>WPZ</strong>) and ACMP Finance Corp. announced that they have issued a notice of redemption to holders of the Issuers' 6.125% Senior Notes due 2022, stating that the Issuers will redeem all of the outstanding Notes for cash on Feb. 23, 2017 at a redemption price equal to 103.063% of the principal amount of the Notes, plus accrued and unpaid interest to the Redemption Date.</li></ul>"